Skip to Main Content (Press Enter)

Logo UNISR
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment

UNIFIND
Logo UNISR

|

UNIFIND

unisr.it
  • ×
  • Home
  • People
  • Outputs
  • Organizations
  • Expertise & Skills
  • Equipment
  1. Outputs

The impact of androgen-deprivation therapy (ADT) on the risk of cardiovascular (CV) events in patients with non-metastatic prostate cancer: a population-based study

Academic Article
Publication Date:
2014
abstract:
Objective To examine and quantify the contemporary association between androgen-deprivation therapy (ADT) and three separate endpoints: coronary artery disease (CAD), acute myocardial infarction (AMI), and sudden cardiac death (SCD), in a large USA contemporary cohort of patients with prostate cancer.Patients and Methods In all, 140474 patients diagnosed with non-metastatic prostate cancer between 1995 and 2009 within the Surveillance, Epidemiology, and End Results (SEER)-Medicare linked database were abstracted. Patients treated with ADT and those not receiving ADT were matched using propensity score methodology. The 10-year CAD, AMI, and SCD rates were estimated. Competing-risks regression analyses tested the association between the type of ADT (GnRH agonists vs bilateral orchidectomy) and CAD, AMI, and SCD, after adjusting for the risk of dying during follow-up.Results Overall, the 10-year rates of CAD, AMI, and SCD were 25.9%, 15.6%, and 15.8%, respectively. After stratification according to ADT status (ADT-naïve vs GnRH agonists vs bilateral orchidectomy), the CAD rates were 25.1% vs 26.9% vs 23.2%, the AMI rates were 14.8% vs 16.6% vs 14.8%, and the SCD rates were 14.2% vs 17.7% vs 16.4%, respectively. In competing-risks multivariable regression analyses, the administration of GnRH agonists (all P < 0.001), but not bilateral orchidectomy (all P ⠥ 0.7), was associated with higher risk of CAD, AMI, and SCD.Conclusions The administration of GnRH agonists, but not orchidectomy, is still associated with a significantly increased risk of CAD, AMI, and, especially, SCD in patients with non-metastatic prostate cancer. Alternative forms of ADT should be considered in patients at higher risk of CV events.
Iris type:
1.1 Articolo in rivista
Keywords:
androgen-deprivation therapy; cardiovascular events; prostate cancer; side-effects; Aged; Androgen Antagonists; Cohort Studies; Coronary Disease; Death, Sudden, Cardiac; Gonadotropin-Releasing Hormone; Humans; Male; Myocardial Infarction; Propensity Score; Prostatic Neoplasms; Risk Factors; SEER Program; United States; Orchiectomy; Urology
List of contributors:
Gandaglia, G; Sun, M; Popa, I; Schiffmann, J; Abdollah, F; Trinh, Qd; Saad, F; Graefen, M; Briganti, A; Montorsi, Francesco; Karakiewicz, Pi
Authors of the University:
BRIGANTI ALBERTO
GANDAGLIA GIORGIO
MONTORSI FRANCESCO
Handle:
https://iris.unisr.it/handle/20.500.11768/17695
Published in:
BJU INTERNATIONAL
Journal
  • Overview

Overview

URL

http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)1464-410X
  • Use of cookies

Powered by VIVO | Designed by Cineca | 26.10.1.0